Ureas

Eisai to Present Abstracts on Lenvatinib at 2021 Gastrointestinal Cancers Symposium

Tuesday, January 12, 2021 - 3:37am

TOKYO, Jan 12, 2021 - (JCN Newswire) - Eisai Co., Ltd. has announced that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, "lenvatinib") will be given at the Gastrointestinal Cancers Symposium Virtual Meeting, from January 15 to 17, 2021.

Key Points: 
  • TOKYO, Jan 12, 2021 - (JCN Newswire) - Eisai Co., Ltd. has announced that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, "lenvatinib") will be given at the Gastrointestinal Cancers Symposium Virtual Meeting, from January 15 to 17, 2021.
  • In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.
  • Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer.
  • Eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these Ricchi, with the aim of contributing to the cure of cancers.

Myovant Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference

Tuesday, January 5, 2021 - 1:30pm

BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences(NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, chief executive officer of Myovant Sciences, Inc., will present at the virtual 39th AnnualJ.P.

Key Points: 
  • BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences(NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, chief executive officer of Myovant Sciences, Inc., will present at the virtual 39th AnnualJ.P.
  • Morgan Healthcare ConferenceonTuesday, January 12, 2021 at 2:50 p.m. Pacific Time.
  • Myovant Sciencesaspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy.
  • Relugolix (120 mg) is FDA-approved as ORGOVYXfor adult patients with advanced prostate cancer.

UPDATE - Sumitovant Biopharma Announces Myovant Sciences and Pfizer Enter Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health

Monday, December 28, 2020 - 2:37pm

Pfizer will also receive an exclusive option to commercialize relugolix in oncology outside the U.S. and Canada, excluding certain Asian countries.

Key Points: 
  • Pfizer will also receive an exclusive option to commercialize relugolix in oncology outside the U.S. and Canada, excluding certain Asian countries.
  • Myovant and Pfizer will equally share profits and certain expenses for ORGOVYX and relugolix combination tablet with Myovant recording revenues.
  • Myovant will remain responsible for regulatory interactions and drug supply and continue to lead clinical development for relugolix combination tablet.
  • Sumitovant is the majority shareholder of Myovant Sciences and Urovant Sciences, and wholly owns Enzyvant Therapeutics, Spirovant Sciences, and Altavant Sciences.

Sumitovant Biopharma Announces Myovant Sciences and Pfizer Enter Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health

Monday, December 28, 2020 - 11:55am

Pfizer will also receive an exclusive option to commercialize relugolix in oncology outside the U.S. and Canada, excluding certain Asian countries.

Key Points: 
  • Pfizer will also receive an exclusive option to commercialize relugolix in oncology outside the U.S. and Canada, excluding certain Asian countries.
  • Myovant and Pfizer will equally share profits and certain expenses for ORGOVYX and relugolix combination tablet with Myovant recording revenues.
  • Myovant will remain responsible for regulatory interactions and drug supply and continue to lead clinical development for relugolix combination tablet.
  • Sumitovant is the majority shareholder of Myovant Sciences and Urovant Sciences, and wholly owns Enzyvant Therapeutics, Spirovant Sciences, and Altavant Sciences.

Sumitovant Biopharma Announces Myovant Sciences receives FDA Approval of ORGOVYXTM (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer

Friday, December 18, 2020 - 10:46pm

Based on findings in animals and mechanism of action, ORGOVYX can cause fetal harm and loss of pregnancy when administered to a pregnant female.

Key Points: 
  • Based on findings in animals and mechanism of action, ORGOVYX can cause fetal harm and loss of pregnancy when administered to a pregnant female.
  • Advise males with female partners of reproductive potential to use effective contraception during treatment and for 2 weeks after the last dose of ORGOVYX.
  • If co-administration is unavoidable, take ORGOVYX first, separate dosing by at least 6 hours, and monitor patients more frequently for adverse reactions.
  • Relugolix (120 mg) is FDA-approved as ORGOVYXTM for adult patients with advanced prostate cancer.

Acer Therapeutics Announces Publication of Vascular Ehlers-Danlos Syndrome (vEDS) Patient Registry Data from Sweden

Thursday, December 17, 2020 - 1:30pm

The publication, entitled Celiprolol Treatment in Patients with Vascular Ehlers-Danlos Syndrome,1 can be found at https://www.ejves.com/action/showPdf?pii=S1078-5884%2820%2930930-8 .

Key Points: 
  • The publication, entitled Celiprolol Treatment in Patients with Vascular Ehlers-Danlos Syndrome,1 can be found at https://www.ejves.com/action/showPdf?pii=S1078-5884%2820%2930930-8 .
  • Patients were followed for a median of 22 months (range 1-98 months) with a total follow up of 106 patient years.
  • Sixty-five percent of the patients reached the target dose of 400 mg and the medication was generally well tolerated.
  • Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial.

The New Normal: Protect Yourself with Face Masks, & Protect Your Skin with the InnerB System® Inner Mask

Wednesday, December 2, 2020 - 5:37pm

To control breakouts and irritation caused by face masks, Aquavit is launching the SKINWORKOUT InnerB System I nner Mask for Blemish Control using its hydrogel technology .

Key Points: 
  • To control breakouts and irritation caused by face masks, Aquavit is launching the SKINWORKOUT InnerB System I nner Mask for Blemish Control using its hydrogel technology .
  • Aquavit secured its inventive rights of PPE-ready inner mask with a worldwide patent process early this year.
  • The skin mask also contains Allantoin, Ulmus Davidiana Root extract, Centraria Islandica extract, and other natural ingredients that soothe and hydrate the skin.
  • The Inner B System Inner Mask is composed of 2 pieces, separated for upper and lower portions of the face.

AVEO Oncology to Present at the Stifel 2020 Virtual Healthcare Conference

Tuesday, November 10, 2020 - 12:00pm

AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020 at 11:20 a.m. Eastern Time.

Key Points: 
  • AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020 at 11:20 a.m. Eastern Time.
  • A live webcast of the presentation can be accessed by visiting the investors section of the Companys website at www.aveooncology.com .
  • AVEO is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients.
  • AVEO is working to develop and potentially commercialize tivozanib in the U.S. as a treatment for renal cell carcinoma and hepatocellular carcinoma.

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrated Statistically Significant Improvement in Progression-Free Survival (PFS), Overall Survival (OS) and Objective Response Rate (ORR) Versus Sunitinib as First-Line Treatment for Patients…

Tuesday, November 10, 2020 - 11:45am

The safety profiles of both KEYTRUDA plus LENVIMA and LENVIMA plus everolimus were consistent with previously reported studies.

Key Points: 
  • The safety profiles of both KEYTRUDA plus LENVIMA and LENVIMA plus everolimus were consistent with previously reported studies.
  • The results from KEYNOTE-581/CLEAR (Study 307) support the potential use of KEYTRUDA plus LENVIMA for the first-line treatment of advanced RCC.
  • KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
  • KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).

TLC Announces Acceptance of Manuscript on Anti-COVID-19 Program by Clinical and Translational Science Journal

Tuesday, November 3, 2020 - 12:37pm

CTS highlights original research that helps bridge laboratory discoveries with the diagnosis and treatment of human disease and is an official journal of the American Society of Clinical Pharmacology and Therapeutics (ASCPT).

Key Points: 
  • CTS highlights original research that helps bridge laboratory discoveries with the diagnosis and treatment of human disease and is an official journal of the American Society of Clinical Pharmacology and Therapeutics (ASCPT).
  • We are honored to be sharing this peer-reviewed manuscript in an internationally acclaimed journal, said George Yeh, President of TLC.
  • CTS has a collection of clinical pharmacology research from various potential treatments such as remdesivir, favipiravir, and lopinavir/ritonavir.
  • Acknowledgment of our work by CTS further fortifies the soundness of our strategy of preferential delivery to the lungs.